Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Kingfisher Cooperative LLC

Neither a doctor nor a teaching hospital

Research payments

$6,812,566

57 payments

Through program year 2025, Kingfisher Cooperative LLC is reported as receiving $6,812,566 in research payments, across 57 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $8,812 1
2024 Research $519,139 4
2023 Research $1,180,861 5
2022 Research $1,490,779 6
2021 Research $2,288,344 4
2020 Research $1,248,989 22
2019 Research $75,642 15

Breakdown

Who paid Research payments · program years 2019–2025
  1. Biogen, Inc. $5,439,597 8 payments
  2. Eli Lilly and Company $1,119,092 13 payments
  3. Eisai Inc. $213,930 16 payments
  4. Teva Pharmaceuticals USA, Inc. $21,757 12 payments
  5. Genentech, Inc. $13,690 7 payments
  6. H. Lundbeck A S $4,500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 $2,841,108 2 payments
  2. A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease $1,195,578 3 payments
  3. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $881,480 7 payments
  4. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $852,294 1 payment
  5. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $550,617 2 payments
  6. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $213,930 16 payments
  7. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $162,688 2 payments
  8. A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease Ad Geras US $74,370 3 payments
  9. Gantenerumab in Early Ad $13,690 7 payments
  10. A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double-Blind, Placebo-Controlled, Parallel-Group Study, Including an Open-Label Period, Evaluating the Efficacy and Safety of 1 Subcutaneous Dose Regimen of Fremanezumab for the Treatment of Posttraumatic Headache (PTH) $11,088 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record